-
1
-
-
0027222768
-
Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis
-
(1993) Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94: 646-650.
-
(1993)
Am J Med
, vol.94
, pp. 646-650
-
-
-
2
-
-
22244432201
-
Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis
-
Cremers SC, Pillai G, Papapoulos SE, (2005) Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 44: 551-570.
-
(2005)
Clin Pharmacokinet
, vol.44
, pp. 551-570
-
-
Cremers, S.C.1
Pillai, G.2
Papapoulos, S.E.3
-
4
-
-
0031672980
-
Meta-analysis about efficacy of anti-resorptive drugs in post-menopausal osteoporosis
-
Macedo JM, Macedo CR, Elkis H, De Oliveira IR, (1998) Meta-analysis about efficacy of anti-resorptive drugs in post-menopausal osteoporosis. J Clin Pharm Ther 23: 345-352.
-
(1998)
J Clin Pharm Ther
, vol.23
, pp. 345-352
-
-
Macedo, J.M.1
Macedo, C.R.2
Elkis, H.3
de Oliveira, I.R.4
-
5
-
-
19544376123
-
Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy
-
Miller PD, (2005) Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy. Clin Ther 27: 361-376.
-
(2005)
Clin Ther
, vol.27
, pp. 361-376
-
-
Miller, P.D.1
-
6
-
-
23944461952
-
Mechanism of action of bisphosphonates
-
Reszka AA, Rodan GA, (2003) Mechanism of action of bisphosphonates. Curr Osteoporos Rep 1: 45-52.
-
(2003)
Curr Osteoporos Rep
, vol.1
, pp. 45-52
-
-
Reszka, A.A.1
Rodan, G.A.2
-
7
-
-
0030842110
-
Bisphosphonate effects and the bone remodeling transient
-
Heaney RP, Yates AJ, Santora AC, (1997) Bisphosphonate effects and the bone remodeling transient. J Bone Miner Res 12: 1143-1151.
-
(1997)
J Bone Miner Res
, vol.12
, pp. 1143-1151
-
-
Heaney, R.P.1
Yates, A.J.2
Santora, A.C.3
-
8
-
-
51749102927
-
Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance
-
Boonen S, Vanderschueren D, Venken K, Milisen K, Delforge M, et al. (2008) Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance. J Intern Med 264: 315-332.
-
(2008)
J Intern Med
, vol.264
, pp. 315-332
-
-
Boonen, S.1
Vanderschueren, D.2
Venken, K.3
Milisen, K.4
Delforge, M.5
-
9
-
-
0035837553
-
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis
-
Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, et al. (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 1434-1441.
-
(2001)
N Engl J Med
, vol.344
, pp. 1434-1441
-
-
Neer, R.M.1
Arnaud, C.D.2
Zanchetta, J.R.3
Prince, R.4
Gaich, G.A.5
-
10
-
-
0141684971
-
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis
-
Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, et al. (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349: 1207-1215.
-
(2003)
N Engl J Med
, vol.349
, pp. 1207-1215
-
-
Black, D.M.1
Greenspan, S.L.2
Ensrud, K.E.3
Palermo, L.4
McGowan, J.A.5
-
11
-
-
38449083492
-
Full length parathyroid hormone (1-84) in the treatment of osteoporosis in postmenopausal women
-
Jodar-Gimeno E, (2007) Full length parathyroid hormone (1-84) in the treatment of osteoporosis in postmenopausal women. Clin Interv Aging 2: 163-174.
-
(2007)
Clin Interv Aging
, vol.2
, pp. 163-174
-
-
Jodar-Gimeno, E.1
-
12
-
-
0345305666
-
Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis
-
Hodsman AB, Hanley DA, Ettinger MP, Bolognese MA, Fox J, et al. (2003) Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 88: 5212-5220.
-
(2003)
J Clin Endocrinol Metab
, vol.88
, pp. 5212-5220
-
-
Hodsman, A.B.1
Hanley, D.A.2
Ettinger, M.P.3
Bolognese, M.A.4
Fox, J.5
-
13
-
-
78449247509
-
Appropriate use of anabolic treatment for severe osteoporosis
-
Adami S, Brandi ML, Canonico PL, Minisola G, Minisola S, et al. (2010) Appropriate use of anabolic treatment for severe osteoporosis. Clin Cases Miner Bone Metab 7: 114-122.
-
(2010)
Clin Cases Miner Bone Metab
, vol.7
, pp. 114-122
-
-
Adami, S.1
Brandi, M.L.2
Canonico, P.L.3
Minisola, G.4
Minisola, S.5
-
14
-
-
78650264647
-
Use of recombinant human parathyroid hormone(1-84) in patients with postmenopausal osteoporosis: a prospective, open-label, single-arm, multicentre, observational cohort study of the effects of treatment on quality of life and pain-the PROPOSE study
-
Moricke R, Rettig K, Bethke TD, (2011) Use of recombinant human parathyroid hormone(1-84) in patients with postmenopausal osteoporosis: a prospective, open-label, single-arm, multicentre, observational cohort study of the effects of treatment on quality of life and pain-the PROPOSE study. Clin Drug Investig 31: 87-99.
-
(2011)
Clin Drug Investig
, vol.31
, pp. 87-99
-
-
Moricke, R.1
Rettig, K.2
Bethke, T.D.3
-
15
-
-
77957063363
-
Bone anabolic versus bone anticatabolic treatment of postmenopausal osteoporosis
-
Lyritis GP, Georgoulas T, Zafeiris CP, (2010) Bone anabolic versus bone anticatabolic treatment of postmenopausal osteoporosis. Ann N Y Acad Sci 1205: 277-283.
-
(2010)
Ann N Y Acad Sci
, vol.1205
, pp. 277-283
-
-
Lyritis, G.P.1
Georgoulas, T.2
Zafeiris, C.P.3
-
16
-
-
20844462737
-
Predictive value of BMD for hip and other fractures
-
Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, et al. (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20: 1185-1194.
-
(2005)
J Bone Miner Res
, vol.20
, pp. 1185-1194
-
-
Johnell, O.1
Kanis, J.A.2
Oden, A.3
Johansson, H.4
de Laet, C.5
-
17
-
-
78649680817
-
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary
-
Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, et al. (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182: 1864-1873.
-
(2010)
CMAJ
, vol.182
, pp. 1864-1873
-
-
Papaioannou, A.1
Morin, S.2
Cheung, A.M.3
Atkinson, S.4
Brown, J.P.5
-
18
-
-
68049137869
-
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
-
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6: e1000100.
-
(2009)
PLoS Med
, vol.6
-
-
Liberati, A.1
Altman, D.G.2
Tetzlaff, J.3
Mulrow, C.4
Gotzsche, P.C.5
-
19
-
-
0029914622
-
Assessing the quality of reports of randomized clinical trials: is blinding necessary?
-
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12.
-
(1996)
Control Clin Trials
, vol.17
, pp. 1-12
-
-
Jadad, A.R.1
Moore, R.A.2
Carroll, D.3
Jenkinson, C.4
Reynolds, D.J.5
-
20
-
-
77951644239
-
Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis
-
Finkelstein JS, Wyland JJ, Lee H, Neer RM, (2010) Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 95: 1838-1845.
-
(2010)
J Clin Endocrinol Metab
, vol.95
, pp. 1838-1845
-
-
Finkelstein, J.S.1
Wyland, J.J.2
Lee, H.3
Neer, R.M.4
-
21
-
-
43749087111
-
Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial
-
Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Koukoulis GN, et al. (2008) Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial. Int J Clin Pract 62: 919-924.
-
(2008)
Int J Clin Pract
, vol.62
, pp. 919-924
-
-
Anastasilakis, A.D.1
Goulis, D.G.2
Polyzos, S.A.3
Gerou, S.4
Koukoulis, G.N.5
-
22
-
-
23744447531
-
Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass
-
McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, et al. (2005) Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165: 1762-1768.
-
(2005)
Arch Intern Med
, vol.165
, pp. 1762-1768
-
-
McClung, M.R.1
San Martin, J.2
Miller, P.D.3
Civitelli, R.4
Bandeira, F.5
-
23
-
-
0141796739
-
The effects of parathyroid hormone, alendronate, or both in men with osteoporosis
-
Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, et al. (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349: 1216-1226.
-
(2003)
N Engl J Med
, vol.349
, pp. 1216-1226
-
-
Finkelstein, J.S.1
Hayes, A.2
Hunzelman, J.L.3
Wyland, J.J.4
Lee, H.5
-
24
-
-
18644374464
-
A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis
-
Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, et al. (2002) A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87: 4528-4535.
-
(2002)
J Clin Endocrinol Metab
, vol.87
, pp. 4528-4535
-
-
Body, J.J.1
Gaich, G.A.2
Scheele, W.H.3
Kulkarni, P.M.4
Miller, P.D.5
-
25
-
-
78649412131
-
Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis
-
Cosman F, Eriksen EF, Recknor C, Miller PD, Guanabens N, et al. (2011) Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res 26: 503-511.
-
(2011)
J Bone Miner Res
, vol.26
, pp. 503-511
-
-
Cosman, F.1
Eriksen, E.F.2
Recknor, C.3
Miller, P.D.4
Guanabens, N.5
-
26
-
-
23444435838
-
Daily and cyclic parathyroid hormone in women receiving alendronate
-
Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, et al. (2005) Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 353: 566-575.
-
(2005)
N Engl J Med
, vol.353
, pp. 566-575
-
-
Cosman, F.1
Nieves, J.2
Zion, M.3
Woelfert, L.4
Luckey, M.5
-
27
-
-
36148958951
-
Teriparatide or alendronate in glucocorticoid-induced osteoporosis
-
Saag KG, Shane E, Boonen S, Marin F, Donley DW, et al. (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357: 2028-2039.
-
(2007)
N Engl J Med
, vol.357
, pp. 2028-2039
-
-
Saag, K.G.1
Shane, E.2
Boonen, S.3
Marin, F.4
Donley, D.W.5
-
28
-
-
30144439980
-
Reduced risk of back pain following teriparatide treatment: a meta-analysis
-
Nevitt MC, Chen P, Dore RK, Reginster JY, Kiel DP, et al. (2006) Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos Int 17: 273-280.
-
(2006)
Osteoporos Int
, vol.17
, pp. 273-280
-
-
Nevitt, M.C.1
Chen, P.2
Dore, R.K.3
Reginster, J.Y.4
Kiel, D.P.5
-
29
-
-
0037214255
-
The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis
-
Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, et al. (2003) The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18: 9-17.
-
(2003)
J Bone Miner Res
, vol.18
, pp. 9-17
-
-
Orwoll, E.S.1
Scheele, W.H.2
Paul, S.3
Adami, S.4
Syversen, U.5
-
30
-
-
33845369453
-
Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk-a meta-analysis
-
Vestergaard P, Jorgensen NR, Mosekilde L, Schwarz P, (2007) Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk-a meta-analysis. Osteoporos Int 18: 45-57.
-
(2007)
Osteoporos Int
, vol.18
, pp. 45-57
-
-
Vestergaard, P.1
Jorgensen, N.R.2
Mosekilde, L.3
Schwarz, P.4
-
31
-
-
0032767389
-
Alendronate increases bone density and bone strength at the distal radius in postmenopausal women
-
Schneider PF, Fischer M, Allolio B, Felsenberg D, Schroder U, et al. (1999) Alendronate increases bone density and bone strength at the distal radius in postmenopausal women. J Bone Miner Res 14: 1387-1393.
-
(1999)
J Bone Miner Res
, vol.14
, pp. 1387-1393
-
-
Schneider, P.F.1
Fischer, M.2
Allolio, B.3
Felsenberg, D.4
Schroder, U.5
-
32
-
-
0033042160
-
Anabolic effects of human biosynthetic parathyroid hormone fragment (1-34), LY333334, on remodeling and mechanical properties of cortical bone in rabbits
-
Hirano T, Burr DB, Turner CH, Sato M, Cain RL, et al. (1999) Anabolic effects of human biosynthetic parathyroid hormone fragment (1-34), LY333334, on remodeling and mechanical properties of cortical bone in rabbits. J Bone Miner Res 14: 536-545.
-
(1999)
J Bone Miner Res
, vol.14
, pp. 536-545
-
-
Hirano, T.1
Burr, D.B.2
Turner, C.H.3
Sato, M.4
Cain, R.L.5
-
33
-
-
0035051721
-
Effects of human parathyroid hormone (1-34), LY333334, on bone mass, remodeling, and mechanical properties of cortical bone during the first remodeling cycle in rabbits
-
Mashiba T, Burr DB, Turner CH, Sato M, Cain RL, et al. (2001) Effects of human parathyroid hormone (1-34), LY333334, on bone mass, remodeling, and mechanical properties of cortical bone during the first remodeling cycle in rabbits. Bone 28: 538-547.
-
(2001)
Bone
, vol.28
, pp. 538-547
-
-
Mashiba, T.1
Burr, D.B.2
Turner, C.H.3
Sato, M.4
Cain, R.L.5
-
34
-
-
77952704223
-
The use of PTH in the treatment of osteoporosis
-
Borba VZ, Manas NC, (2010) The use of PTH in the treatment of osteoporosis. Arq Bras Endocrinol Metabol 54: 213-219.
-
(2010)
Arq Bras Endocrinol Metabol
, vol.54
, pp. 213-219
-
-
Borba, V.Z.1
Manas, N.C.2
-
36
-
-
0036001310
-
Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety
-
Vahle JL, Sato M, Long GG, Young JK, Francis PC, et al. (2002) Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 30: 312-321.
-
(2002)
Toxicol Pathol
, vol.30
, pp. 312-321
-
-
Vahle, J.L.1
Sato, M.2
Long, G.G.3
Young, J.K.4
Francis, P.C.5
-
37
-
-
23444452077
-
One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis
-
Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, et al. (2005) One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 353: 555-565.
-
(2005)
N Engl J Med
, vol.353
, pp. 555-565
-
-
Black, D.M.1
Bilezikian, J.P.2
Ensrud, K.E.3
Greenspan, S.L.4
Palermo, L.5
-
38
-
-
0034458020
-
Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate
-
Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, et al. (2000) Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85: 2129-2134.
-
(2000)
J Clin Endocrinol Metab
, vol.85
, pp. 2129-2134
-
-
Rittmaster, R.S.1
Bolognese, M.2
Ettinger, M.P.3
Hanley, D.A.4
Hodsman, A.B.5
|